Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Axitinib by Pfizer for Cervical Cancer: Likelihood of Approval
Axitinib is under clinical development by Pfizer and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...
Axitinib by Pfizer for Salivary Gland Cancer: Likelihood of Approval
Axitinib is under clinical development by Pfizer and currently in Phase II for Salivary Gland Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Ocular Therapeutix's Axitinib?
Axitinib is a small molecule commercialized by Ocular Therapeutix, with a leading Phase III program in Wet (Neovascular / Exudative)...
Axitinib by Clearside BioMedical for Wet (Neovascular / Exudative) Macular Degeneration: Likelihood of Approval
Axitinib is under clinical development by Clearside BioMedical and currently in Phase II for Wet (Neovascular / Exudative) Macular Degeneration....
Risk adjusted net present value: What is the current valuation of Clearside BioMedical's Axitinib?
Axitinib is a small molecule commercialized by Clearside BioMedical, with a leading Phase II program in Wet (Neovascular / Exudative)...
Risk adjusted net present value: What is the current valuation of Ocular Therapeutix's Axitinib?
Axitinib is a small molecule commercialized by Ocular Therapeutix, with a leading Phase III program in Wet (Neovascular / Exudative)...